Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine

Vaccine
Erin R ShanahanNicholas P West

Abstract

Infection with Mycobacterium tuberculosis continues to be a leading cause of death in many regions of the world, and control of this disease is hampered by the lack of a safe and effective vaccine. Secreted proteins of M. tuberculosis are an important group of antigens for subunit vaccines which target this infection. We have tested three secreted members of the cutinase-like protein (CULP) family of M. tuberculosis for their potential as protein vaccine antigens. Culp6 elicited a strong T lymphocyte response in M. tuberculosis infected mice, and importantly, in tuberculosis (TB) patients tested. Culp1, Culp2 and Culp6 when delivered as protein vaccines to mice, induced potent IFN-gamma responses which in turn translated into a significant level of protection against aerosol M. tuberculosis infection. A Culp1-6 fusion protein provided an increased level of protection against infection compared to Culp1 or Culp6 alone. The data presented here may indicate that the cell wall-associated, putatively essential protein Culp6, shown here for the first time to be recognised in TB patients, is an attractive candidate for inclusion in future subunit vaccines.

References

Jan 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·T F Brewer, G A Colditz
Feb 10, 1999·The Journal of Infectious Diseases·P RavnP Andersen
Mar 17, 1999·FEMS Immunology and Medical Microbiology·K Weldingh, P Andersen
Jan 20, 2000·Infection and Immunity·L BrandtP Andersen
Mar 27, 2003·Molecular Microbiology·Christopher M SassettiEric J Rubin
Mar 21, 2006·Lancet·Christopher Dye
May 20, 2006·Nature Reviews. Microbiology·Yasir A W Skeiky, Jerald C Sadoff
Aug 22, 2006·Scandinavian Journal of Immunology·H G WikerA M D Riise
Aug 23, 2006·Archives of Disease in Childhood·V WalkerI Wacogne
Jun 28, 2008·The Journal of Infectious Diseases·Tony HawkridgeHelen McShane
Feb 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Steven G ReedYves Lobet
Feb 20, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Nicholas P WestWarwick J Britton
Jun 3, 2009·Infection and Immunity·H Martin VordermeierR Glyn Hewinson

❮ Previous
Next ❯

Citations

Mar 2, 2016·International Journal of Mycobacteriology·Shivangi RastogiManju Y Krishnan
Jun 17, 2016·Microbiology and Molecular Biology Reviews : MMBR·Marietta Flores-DíazAntje Flieger
Sep 27, 2018·Future Microbiology·Nagender Rao RameshwaramSangita Mukhopadhyay
May 27, 2010·Critical Reviews in Microbiology·Gurdyal SinghJagdeep Kaur
Apr 6, 2018·Scientific Reports·Emily J Strong, Nicholas P West
Dec 17, 2020·Pharmaceutics·Zhi Ming TanHira Choudhury
Oct 28, 2021·Applied and Environmental Microbiology·Kofi AbokitsePeter C K Lau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.